10-K: Biofrontera Reports Improved 2025 Results Amid Going Concern Doubt

Biofrontera Inc. reported an 11.8% revenue increase and reduced net loss in 2025, driven by a strategic acquisition and cost efficiencies, despite facing substantial doubt about its ability to continue as a going concern.

Summary

• Net product revenue increased by $4.4 million, or 11.8%, to $41.7 million in 2025 compared to $37.3 million in 2024, primarily due to organic growth in Ameluz sales volume and an increased unit price.
• The company's net loss improved significantly, decreasing to $(10.5) million in 2025 from $(17.8) million in 2024.
• Adjusted EBITDA improved from $(15.3) million in 2024 to $(10.6) million in 2025, with the Adjusted EBITDA margin increasing from -40.9% to -25.4%.
• Biofrontera acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG on October 20, 2025, transitioning from a transfer pricing model to an earnout structure (12-15% of U.S. revenues), which is expected to reduce overall costs and accelerate the timeframe to reach break-even.
• The company completed the sale of its Xepi product line's intangible asset for initial proceeds of $3 million, with potential for up to an additional $7 million in milestone payments.
• Research and development expenses increased by $1.6 million in 2025, primarily due to assuming full control of Ameluz clinical trials in the U.S. since June 1, 2024.
• A Supplemental New Drug Application (sNDA) for Ameluz in superficial basal cell carcinoma (sBCC) was submitted to the FDA in November 2025, with a Prescription Drug User Fee Act (PDUFA) date set for September 28, 2026.
• The FDA approved an increase in the maximally approved dosage of Ameluz from one to three tubes per treatment in October 2024, enhancing treatment flexibility.
• A new Ameluz formulation without propylene glycol, protected by a patent extending to 2043, has been implemented in all U.S. productions since 2024.
• The company received a Nasdaq non-compliance notice on December 31, 2025, for its common stock bid price falling below $1.00 for 34 consecutive business days, with a compliance period until June 30, 2026.
• As of December 31, 2025, the company had an accumulated deficit of $127.9 million and cash and cash equivalents of $6.4 million.
• Management has determined that substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the report's issuance date.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a low score due to the explicit 'substantial doubt about our ability to continue as a going concern,' which overshadows the reported operational improvements and strategic moves. While revenue growth and reduced net loss are positive trends, the fundamental liquidity risk is a critical concern for investors.

Positives

• Net product revenue increased by 11.8% to $41.7 million in 2025, demonstrating organic growth in Ameluz sales volume and unit price.
• Net loss significantly improved from $(17.8) million in 2024 to $(10.5) million in 2025.
• Adjusted EBITDA improved by $4.7 million, from $(15.3) million in 2024 to $(10.6) million in 2025, indicating better operational efficiency.
• The strategic acquisition of U.S. rights to Ameluz and RhodoLED is expected to reduce overall costs and accelerate the timeframe to reach break-even.
• A Supplemental New Drug Application (sNDA) for Ameluz in superficial basal cell carcinoma (sBCC) was submitted to the FDA in Q4 2025, with a PDUFA date of September 28, 2026, indicating pipeline progress.
• FDA approval in October 2024 to increase Ameluz dosage from one to three tubes per treatment provides greater flexibility for healthcare professionals and patients.
• A new Ameluz formulation, protected by a patent extending to 2043, enhances product stability and intellectual property protection.
• The sale of the Xepi product line generated initial proceeds of $3 million, with potential for an additional $7 million in milestone payments.

Negatives

• The company has a history of operating losses, with an accumulated deficit of $127.9 million as of December 31, 2025.
• Management has determined that substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the report's issuance date.
• The company received a Nasdaq non-compliance notice on December 31, 2025, due to its common stock bid price falling below $1.00, risking delisting.
• Operating activities used $13.4 million in cash in 2025, indicating continued cash burn.
• Selling, general and administrative expenses increased by $4.0 million, or 11.7%, primarily due to higher external legal costs related to patent claims.
• The company's current capital resources are not adequate to continue operating and maintaining its business strategy for a period of twelve months.

Risks

• Generic versions of Ameluz entering the market could significantly reduce its price and market share.
• Inability to successfully obtain and maintain regulatory approvals or reimbursement for Ameluz for existing and additional indications could materially harm the business.
• Failure by the company or its manufacturing partners to produce products in sufficient quantities, at acceptable quality and cost, or to comply with cGMP could lead to commercialization delays or lost revenues.
• Breakdowns, failures, or suboptimal performance of manufacturing equipment could disrupt operations, increase costs, and impair product quality.
• Inadequate protection of intellectual property rights could hinder competitive effectiveness.
• Ongoing and future intellectual property lawsuits could be expensive, time-consuming, and unsuccessful.
• International business dealings with manufacturing partners may pose currency risks.
• Competing products and future emerging products may erode sales of current products.
• Geopolitical instability, trade disputes, and tariffs could increase costs, disrupt the supply chain, and adversely affect financial results.
• Limited or unavailable insurance coverage and medical expense reimbursement in certain market segments could make product sales difficult.
• Healthcare legislative changes could materially adversely affect business and results of operations.
• Inability to maintain effective marketing and sales capabilities or establish GPO relationships could jeopardize future revenues and profitability.
• The estimated U.S. market size for Ameluz for AK treatment may be smaller than anticipated.
• Even with additional regulatory approvals, new product indications may not gain market acceptance.
• Failure to comply with extensive healthcare laws and regulations could result in penalties and harm to business and reputation.
• Product recalls or discovery of serious safety issues could have a significant negative impact.
• High dependence on key personnel, and inability to attract and retain qualified staff, could hinder business strategy implementation.
• Difficulties in managing organizational growth could impact financial performance and commercialization goals.
• System failures or cyber-attacks could disrupt operations, lead to data breaches, and incur liabilities.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Subsidiary and third-party employees being subject to foreign laws (e.g., German Act on Employees Inventions) could lead to disputes and increased costs.
• Third-party claims of intellectual property infringement may affect the ability to sell products or delay R&D efforts.
• Uncertainty of R&D efforts, with no assurance of enhancing commercial success.
• Substantial doubt about the ability to continue as a going concern.
• History of operating losses and uncertainty of achieving sustained profitability.
• Failure to obtain additional financing could prevent strategic growth plans.
• Existing and future indebtedness could adversely affect business operations.
• Delay or termination of planned clinical trials for indication expansion would result in unplanned expenses and impact commercial prospects.
• Products posing safety issues, causing adverse events, or having side effects could delay or prevent regulatory approval of additional indications.
• Lengthy, time-consuming, and unpredictable regulatory approval processes for additional indications could substantially harm the business.
• Reliance on third parties for clinical trials means their failure to meet duties or deadlines could delay regulatory approval.
• Failure to maintain an effective system of internal controls could impair financial reporting and investor confidence.
• Share price volatility, influenced by various factors, could lead to substantial declines.
• Failure to regain and maintain Nasdaq listing compliance could result in delisting.
• Exercise of warrants and conversion of preferred stock could result in significant dilution to stockholders.
• Future sales and issuances of common stock could result in additional dilution and stock price decline.
• Certain provisions in outstanding warrants, charter documents, and Delaware law could prevent a favorable takeover and reduce stock price.
• Warrants accounted for as a liability, with fair value changes reported in earnings, may adversely affect the market price of common stock.

Future Outlook

The company's strategy focuses on expanding U.S. sales of Ameluz PDT for actinic keratosis (AK) to establish it as the standard of care, leveraging new label indications, and acquiring new customers. Future plans include advancing clinical development for Ameluz, particularly for label extensions in moderate to severe acne and AK on the trunk and extremities, with regulatory filings expected in Q3 2026 for the latter. Enrollment for an AK Pain Reduction study is planned for 2027. The company also aims to strategically manage its portfolio by opportunistically adding complementary products or services through acquisitions or licensing to leverage its commercial infrastructure.

Management Comments

• Our principal objective is to improve patient outcomes in the non-melanoma space through adoption and use of our products.
• The new structure (post-Strategic Transaction) reduces overall cost for the Company and is expected to accelerate the Company's timeframe to reach break-even.

Industry Context

StockSavvy.ai notes that Biofrontera operates in the competitive dermatology market, specifically targeting actinic keratosis (AK), the most common precancer. While cryotherapy dominates 86% of the AK market and topicals hold 12%, PDT, including Ameluz, currently accounts for only 2%. The total AK market is estimated at $4 billion. Biofrontera's primary PDT competitor is Levulan and its associated light, Blu-U. The company's strategy to convert cryotherapy treatments for more than 14 lesions to Ameluz PDT targets an estimated $500 million segment of the AK market. The industry is also influenced by group purchasing organizations (GPOs) exerting pressure on pricing and by evolving healthcare legislation like the Inflation Reduction Act (IRA) and 340B Drug Discount Program, which impact drug coverage and pricing.

Comparison to Industry Standards

• Ameluz PDT demonstrates high efficacy with up to 91% clearance after one or two treatments for AK, which is competitive with or superior to the estimated 86% efficacy of traditional cryotherapy.
• International treatment guidelines list PDT as the gold standard for treating AK, especially multiple AKs and surrounding photodamaged skin, positioning Ameluz favorably against less effective or scarring treatments like cryotherapy.
• The company's focus on expanding into the $500 million segment of the AK market for patients with more than 14 lesions indicates a strategic move to differentiate from competitors like Levulan/Blu-U and traditional cryotherapy, which may not be as effective for field-directed treatment.
• The FDA approval to increase Ameluz dosage and the development of the RhodoLED XL lamp allow for treatment of larger areas, addressing a limitation compared to older PDT methods or single-lesion treatments.

Management Changes

Corporate Governance

Legal Proceedings

• DUSA Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries LTD (SUN) filed a complaint on September 13, 2023, alleging breach of contract, Lanham Act violation, and unfair trade practices related to Biofrontera's Ameluz product marketing. This case was transferred to the U.S. District Court for the District of New Jersey, and Biofrontera filed counterclaims.
• SUN filed two complaints on June 26 and 27, 2024, against Biofrontera and its affiliates, alleging that the RhodoLED-XL infringes two patents held by SUN. One case is held in abeyance pending an International Trade Commission (ITC) investigation.
• On September 30, 2025, an ITC Administrative Law Judge (ALJ) issued an Initial Determination finding SUN's patents valid and that importation of Biofrontera's RhodoLED XL violates Section 337 of the Tariff Act of 1930. This ID is subject to review by the Commission, with a Final Determination expected by April 30, 2026.
• Biofrontera challenged the validity of SUN's patents at the U.S. Patent Trial and Appeal Board (PTAB). One petition was denied, but on February 23, 2026, the PTAB issued a final written decision finding all challenged claims in one of the SUN Patents to be unpatentable.

Related Party Transactions

• On October 20, 2025, the company completed a Strategic Transaction with Biofrontera AG and its consolidated subsidiaries (Biofrontera Group) to acquire all U.S. rights to Ameluz and RhodoLED.
• The Strategic Transaction involved an earnout agreement, retroactive to June 1, 2025, where the company pays 12% of U.S. Ameluz revenues (up to $65.0 million) and 15% (above $65.0 million) until patent expiration, replacing a previous transfer pricing model.
• In exchange for U.S. rights, Biofrontera AG received 3,019 shares of Series D Convertible Preferred Stock, representing a 10% post-money equity stake.
• The company assumed defense costs for co-defendant Biofrontera Group in certain U.S. legal actions.
• Amounts due and payable to Biofrontera Group were $4.8 million as of December 31, 2025, and $5.3 million as of December 31, 2024.
• Amounts due from Biofrontera Group were $0.7 million as of December 31, 2025.
• Inventory purchases from Biofrontera Group were $7.1 million in 2025 and $8.3 million in 2024.
• Earnout payments of $2.2 million were expensed in 2025 in connection with the Strategic Transaction.
• Other payments to Biofrontera Group for services (production, quality control, pharmacovigilance, regulatory, rent) were $0.8 million in 2025 and $0.5 million in 2024.
• The company holds an investment of 3,019 common shares of Biofrontera AG, with minimal value as of December 31, 2025 and 2024.
• In November 2024, the company issued $4.2 million in Senior Secured Convertible Notes to certain principal stockholders.

Stakeholder Impact

• Shareholders face significant dilution risk from outstanding warrants and convertible preferred stock, as well as potential future equity financings.
• Shareholders are exposed to high volatility in share price and the risk of delisting from Nasdaq due to non-compliance with listing standards.
• Employees may experience uncertainty due to the company's going concern doubt, but the company's growth plans and equity incentive programs aim to attract and retain talent.
• Customers (dermatology offices and groups) benefit from the company's focus on expanding Ameluz sales and R&D for new indications and improved lamps, but may face pricing pressures from GPOs.
• Suppliers, particularly Midas Pharma GmbH for API, are critical to the company's supply chain, and the company is working to secure stable supply.
• Creditors (holders of convertible notes) are secured by substantially all company property, but the going concern doubt presents a risk to repayment.

Next Steps

• Continue to expand the commercialization of Ameluz in the United States while controlling expenses.
• Seek to secure additional capital through equity or debt financings to address going concern issues.
• Pursue regulatory approval for Ameluz in superficial basal cell carcinoma (sBCC), with a PDUFA date of September 28, 2026.
• Advance clinical development for Ameluz label extensions, including regulatory filing for AK on trunk and extremities in Q3 2026.
• Initiate enrollment for the Ameluz Actinic Keratosis Pain Reduction study in 2027.
• Regain compliance with Nasdaq's minimum bid price rule by June 30, 2026, to avoid delisting.
• Implement necessary licenses and contracts to fully assume manufacturing responsibilities for Ameluz and RhodoLED Lamps, transitioning from the Former Ameluz Licensor.
• Monitor and potentially realize an additional $1.0 million in milestone payments from the sale of the Xepi intangible asset.

Key Dates

Recommendation

Despite some operational improvements in 2025, the explicit 'substantial doubt about our ability to continue as a going concern' is a critical red flag that fundamentally undermines the company's viability. The Nasdaq non-compliance notice and the need for significant additional financing within 12 months indicate severe liquidity issues. While the strategic transaction and R&D pipeline offer potential long-term value, the immediate financial instability and high risk of delisting make this stock a 'strong sell' for any seasoned investor or institution, as capital preservation should be prioritized over speculative upside in such a precarious situation.

Keywords

Biofrontera, BFRI, Ameluz, RhodoLED, Photodynamic Therapy, PDT, Actinic Keratosis, AK, Dermatology, Biopharmaceutical, SEC Filing, 10-K, Financial Results, Going Concern, Nasdaq Compliance, Intellectual Property, Clinical Trials, Superficial Basal Cell Carcinoma, sBCC, Drug Master File, DMF, Warrants, Convertible Preferred Stock